Meral Beksac

Jul 15, 2024 | emjreviews.com | Meral Beksac |Mohamad Mohty

IMROZ represents a landmark study in multiple myeloma and is the first global Phase III study of an anti-CD38 monoclonal antibody (mAb) in combination with standard-of-care bortezomib, lenalidomide, and dexamethasone (VRd) to show a significant improvement in progression-free survival (PFS), together with deep and sustained responses, in newly-diagnosed patients not intended for transplant.

Jan 30, 2024 | nature.com | Meral Beksac |Xavier Poiré |Ali Bazarbachi |Thomas Pabst |Jürgen Finke |Inken Hilgendorf | +3 more

AbstractBortezomib (Vel)- Melphalan 200 mg/m2 (Mel200) (Vel-Mel) has been utilised to intensify conditioning in autologous hematopoietic stem cell transplantation (AHCT) for multiple myeloma (MM). This EBMT registry-based study compared Vel-Mel with Mel200 during upfront AHCT. Between 2010 and 2017, MM patients who received Vel-Mel (n = 292) conditioning were compared with 4,096 Mel200 patients in the same 58 centres.

Dec 7, 2023 | nature.com | Elias K. Mai |Hans Salwender |Marc S. Raab |Katia Mancuso |Meral Beksac |Ullrich Graeven | +6 more

AbstractEarly morbidity and mortality affect patient outcomes in multiple myeloma. Thus, we dissected the incidence and causes of morbidity/mortality during induction therapy (IT) for newly diagnosed multiple myeloma (NDMM), and developed/validated a predictive risk score. We evaluated 3700 transplant-eligible NDMM patients treated in 2005–2020 with novel agent-based triplet/quadruplet IT. Primary endpoints were severe infections, death, or a combination of both.

Sep 28, 2023 | onclive.com | Meral Beksac

Meral Beksac, MD, director of Department of Hematology, Ankara University, Turkey, discusses overall survival (OS) data from the phase 3 OPTIMISMM trial (NCT01734928) in patients with relapsed/refractory multiple myeloma. OPTIMISMM evaluated the addition of pomalidomide (Pomalyst) to bortezomib (Velcade) and dexamethasone (PVd; n = 281) vs Vd alone (n = 278) in patients with relapsed/refractory multiple myeloma.

May 9, 2023 | nature.com | Meral Beksac |Patrice Chevallier |John A Snowden |Monika Engelhardt |Donal McLornan |Patrick J. Hayden | +1 more

AbstractEarly relapse (ER) following Autologous Hematopoietic Cell Transplantation (AHCT) confers a poor prognosis. We therefore developed a novel scoring system to predict ER. A total of 14,367 AHCT-1 patients were transplanted between 2014 and 2019, and were conditioned with Melphalan 200 mg/m2 (Mel200) (n = 7228; 2014–2017) (training cohort); Mel200 (n = 5616; 2018–2019) or Mel140 (n = 1523; 2018–2019) (validation cohorts).